GNT Pharma Provides Update on Two Phase III Studies of Nelonemdaz for Acute Ischemic Stroke Patients Treated with tPA (ENIS-3) or Endovascular Thrombectomy (RODIN)
19. September 2022 09:00 ET
|
GNT Pharma Co., Ltd
Promising efficacy and safety profiles were observed in prior Phase II studies in acute ischemic stroke patients treated with recanalization therapies. The ENIS-3 trial has achieved >33% of...
GNT Pharma Announces Approval of IND Application for the Phase III RODIN Trial of Nelonemdaz for Acute Ischemic Stroke Patients
08. September 2021 06:00 ET
|
GNT Pharma Co., Ltd
PIII Study for 496 ischemic stroke patients treated with endovascular thrombectomyFirst multi-target neuroprotectant for the intervention of ischemic brain injurySafety and efficacy verified in two...